TrialMolecular oncology2014

Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer.

Xiaoli Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.